Canaccord Genuity Reiterates a 'Buy' on Stryker (SYK); New Hip Product Cycle Drives Recon Stabilization; MedSurg Keeps Chugging
Tweet
Share
E-mailGet Alerts SYK Hot Sheet
Price: $338.67 -0.39%
Rating Summary:
33 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
33 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Stryker (NYSE: SYK) price target raised $1 to $69.50.
Canaccord analyst says, "We continue to be long-term buyers of Stryker given the continued stabilization shown by its large joint recon business (primarily across its hip business) as well as the continued strength in its MedSurg franchise. Additionally, we believe synergies and distribution from recent acquisitions will likely drive continued growth and operating leverage over the next 12-18 months."
For more ratings news on Stryker click here and for the rating history of Stryker click here.
Shares of Stryker closed at $49.41 yesterday.
Canaccord analyst says, "We continue to be long-term buyers of Stryker given the continued stabilization shown by its large joint recon business (primarily across its hip business) as well as the continued strength in its MedSurg franchise. Additionally, we believe synergies and distribution from recent acquisitions will likely drive continued growth and operating leverage over the next 12-18 months."
For more ratings news on Stryker click here and for the rating history of Stryker click here.
Shares of Stryker closed at $49.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- Wolfe Research Downgrades Stryker (SYK) to Peerperform
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
